Drug application
SERENTIL (MESORIDAZINE BESYLATE)
Drugs@FDA NDA 016774 · NOVARTIS
Key facts
| Drug name | SERENTIL |
|---|---|
| Active ingredients | MESORIDAZINE BESYLATE |
| Application type | NDA |
| Application number | 016774 |
| Company | NOVARTIS |
| Dosage forms | TABLET, ORAL |
| Strength | EQ 10MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission class | Type 1 - New Molecular Entity |
| Latest submission status date | Feb 27, 1970 |
At a glance
- 1–9 Submissions
- 10–99 Supplements
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: